574 related articles for article (PubMed ID: 28527613)
1. No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.
Salvador S; Scott S; Francis JA; Agrawal A; Giede C
J Obstet Gynaecol Can; 2017 Jun; 39(6):480-493. PubMed ID: 28527613
[TBL] [Abstract][Full Text] [Related]
2. Guideline No. 403: Initial Investigation and Management of Adnexal Masses.
Salvador S; Scott S; Glanc P; Eiriksson L; Jang JH; Sebastianelli A; Dean E
J Obstet Gynaecol Can; 2020 Aug; 42(8):1021-1029.e3. PubMed ID: 32736853
[TBL] [Abstract][Full Text] [Related]
3. No. 370-Management of Squamous Cell Cancer of the Vulva.
Francis JA; Eiriksson L; Dean E; Sebastianelli A; Bahoric B; Salvador S
J Obstet Gynaecol Can; 2019 Jan; 41(1):89-101. PubMed ID: 30580832
[TBL] [Abstract][Full Text] [Related]
4. No. 385-Indications for Pelvic Examination.
Evans D; Goldstein S; Loewy A; Altman AD
J Obstet Gynaecol Can; 2019 Aug; 41(8):1221-1234. PubMed ID: 31331610
[TBL] [Abstract][Full Text] [Related]
5. Guideline No. 390-Classification and Management of Endometrial Hyperplasia.
Auclair MH; Yong PJ; Salvador S; Thurston J; Colgan TTJ; Sebastianelli A
J Obstet Gynaecol Can; 2019 Dec; 41(12):1789-1800. PubMed ID: 31785798
[TBL] [Abstract][Full Text] [Related]
6. Guideline No. 408: Management of Gestational Trophoblastic Diseases.
Eiriksson L; Dean E; Sebastianelli A; Salvador S; Comeau R; Jang JH; Bouchard-Fortier G; Osborne R; Sauthier P
J Obstet Gynaecol Can; 2021 Jan; 43(1):91-105.e1. PubMed ID: 33384141
[TBL] [Abstract][Full Text] [Related]
7. No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
Jacobson M; Bernardini M; Sobel ML; Kim RH; McCuaig J; Allen L
J Obstet Gynaecol Can; 2018 Nov; 40(11):1497-1510. PubMed ID: 30473125
[TBL] [Abstract][Full Text] [Related]
8. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
[TBL] [Abstract][Full Text] [Related]
9. Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada.
Hanley GE; Kwon JS; Finlayson SJ; Huntsman DG; Miller D; McAlpine JN
Am J Obstet Gynecol; 2018 Aug; 219(2):172.e1-172.e8. PubMed ID: 29852159
[TBL] [Abstract][Full Text] [Related]
10. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone.
van Lieshout LAM; Steenbeek MP; De Hullu JA; Vos MC; Houterman S; Wilkinson J; Piek JM
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012858. PubMed ID: 31456223
[TBL] [Abstract][Full Text] [Related]
11. Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada.
Hanley GE; Kwon JS; McAlpine JN; Huntsman DG; Finlayson SJ; Miller D
Am J Obstet Gynecol; 2020 Aug; 223(2):221.e1-221.e11. PubMed ID: 32067967
[TBL] [Abstract][Full Text] [Related]
12. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas.
Gilks CB; Irving J; Köbel M; Lee C; Singh N; Wilkinson N; McCluggage WG
Am J Surg Pathol; 2015 Mar; 39(3):357-64. PubMed ID: 25517954
[TBL] [Abstract][Full Text] [Related]
13. The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage.
Naumann RW; Hughes BN; Brown J; Drury LK; Herzog TJ
Am J Obstet Gynecol; 2021 Oct; 225(4):397.e1-397.e6. PubMed ID: 33798477
[TBL] [Abstract][Full Text] [Related]
14. Beyond Sterilization: A Comprehensive Review on the Safety and Efficacy of Opportunistic Salpingectomy as a Preventative Strategy for Ovarian Cancer.
Zadabedini Masouleh T; Etchegary H; Hodgkinson K; Wilson BJ; Dawson L
Curr Oncol; 2023 Nov; 30(12):10152-10165. PubMed ID: 38132373
[TBL] [Abstract][Full Text] [Related]
15. Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How?
Catanzarite T; Eskander RN
Female Pelvic Med Reconstr Surg; 2020 Jun; 26(6):401-406. PubMed ID: 31135579
[TBL] [Abstract][Full Text] [Related]
16. No. 351-Transvaginal Mesh Procedures for Pelvic Organ Prolapse.
Larouche M; Geoffrion R; Walter JE
J Obstet Gynaecol Can; 2017 Nov; 39(11):1085-1097. PubMed ID: 29080723
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?
Kotsopoulos J; Narod SA
Int J Cancer; 2020 Sep; 147(5):1245-1251. PubMed ID: 32037528
[TBL] [Abstract][Full Text] [Related]
18. Primary prevention of ovarian cancer: a patient decision aid for opportunistic salpingectomy.
van Lieshout LAM; Gelderblom ME; de Hullu JA; The R; van Ginkel AA; Oerlemans AJM; Smeets KMWH; Schreurs MPH; Piek JMJ; Hermens RPMG
Am J Obstet Gynecol; 2022 Feb; 226(2):234.e1-234.e14. PubMed ID: 34536392
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of opportunistic salpingectomy vs tubal ligation at the time of cesarean delivery.
Venkatesh KK; Clark LH; Stamilio DM
Am J Obstet Gynecol; 2019 Jan; 220(1):106.e1-106.e10. PubMed ID: 30170036
[TBL] [Abstract][Full Text] [Related]
20. No. 377-Hysterectomy for Benign Gynaecologic Indications.
Thurston J; Murji A; Scattolon S; Wolfman W; Kives S; Sanders A; Leyland N
J Obstet Gynaecol Can; 2019 Apr; 41(4):543-557. PubMed ID: 30879487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
